Welcome!

News Feed Item

Biotech Equities Technical Analysis -- BioMarin Pharma, Merrimack Pharma, Sangamo BioSciences, ZIOPHARM Oncology, and Dyax

Editor Note: For more information about this release, please scroll to bottom.

LONDON, August 7, 2014 /PRNewswire/ --

On Wednesday, August 06, 2014, the NASDAQ Composite ended at 4,355.05, up 0.05%, the Dow Jones Industrial Average finished the day 0.08% higher at 16,443.34, and the S&P 500 closed flat at 1,920.24. However the gains were not broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 700.41, down 0.12%, and the index has declined 2.91% in the last one month. Investor-Edge has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Sangamo BioSciences Inc. (NASDAQ: SGMO), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Dyax Corporation (NASDAQ: DYAX). Free research on these five companies can be accessed at:  

http://investor-edge.com/register

On Wednesday, BioMarin Pharmaceutical Inc.'s stock recorded a trading volume of 0.99 million shares, lower than its three months average volume of 1.25 million shares. The stock finished the day at $65.11, up 0.23%, and registered an intraday range of $64.18 and $65.49. Shares of BioMarin Pharmaceutical Inc. have advanced 0.81% in the last one month and 10.73% in the past three months. However, the stock has declined 7.45% on YTD basis. Furthermore, the stock is trading above its 50-day moving average. The stock's 200-day moving average of $66.28 is above its 50-day moving average of $61.09. Additionally, shares of BioMarin Pharmaceutical Inc. have a Relative Strength Index (RSI) of 65.01. Sign up and read the free notes on BMRN at:

http://www.Investor-Edge.com/BMRN-07Aug2014

Merrimack Pharmaceuticals Inc.'s stock gained 0.51%, to close Wednesday's session at $5.96, after oscillating between $5.88 and $6.05. The stock recorded a trading volume of 0.77 million shares, below its three months average volume of 1.74 million shares. Over the past three trading sessions and from the beginning of 2014, Merrimack Pharmaceuticals Inc.'s shares have gone up 3.11% and 11.80%, respectively. However, over the last one month, the stock has fallen by 20.11%. The company's shares are trading above their 200-day moving average. The stock's 50-day moving average of $6.98 is above its 200-day moving average of $5.43. Further, Merrimack Pharmaceuticals Inc.'s stock has an RSI of 41.02. The complimentary notes on MACK can be downloaded as in PDF format at:

http://www.Investor-Edge.com/MACK-07Aug2014

On Wednesday, shares in Sangamo BioSciences Inc. finished the session 2.21% lower at $13.30. A total of 0.67 million shares were traded, which was below its three months average volume of 0.88 million shares. The stock moved between $13.14 and $13.71 during the session. Over the past three trading sessions and last three months, Sangamo BioSciences Inc.'s shares have surged 7.87% and 2.94%, respectively. However, the stock has lost 4.25% since the start of this year. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $14.98 is greater than its 50-day moving average of $14.11. Shares of Sangamo BioSciences Inc. have an RSI of 53.24. Register for free on Investor-Edge and access the latest research on SGMO at:

http://www.Investor-Edge.com/SGMO-07Aug2014

ZIOPHARM Oncology Inc.'s stock fluctuated between $3.12 and $3.27 before ending Wednesday's session up 2.54%, at $3.23. The stock reported a trading volume of 0.32 million shares, below its three months average volume of 0.79 million shares. Further, ZIOPHARM Oncology Inc.'s shares have gained 7.67% over the past three trading sessions. However, the stock has plummeted 19.45% over the last one month and 25.58% on YTD basis. The stock is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $3.94 is greater than its 50-day moving average of $3.69. Moreover, shares of ZIOPHARM Oncology Inc. have an RSI of 40.36. The complete research on ZIOP is available for free at:

http://www.Investor-Edge.com/ZIOP-07Aug2014

Dyax Corp.'s stock fell by 1.27%, to close Wednesday's session at $9.33, after vacillating between $9.24 and $9.54. The stock recorded a trading volume of 0.97 million shares, below its three months average volume of 1.23 million shares. Over the last one month, Dyax Corp.'s shares have fallen by 5.28%. However, over the past three months and from the beginning of 2014, the stock has rallied 47.16% and 23.82%, respectively. The company's shares are trading above their 50-day and 200-day moving averages. The stock's 50-day moving average of $8.81 is above its 200-day moving average of $8.29. Further, Dyax Corp.'s stock has an RSI of 56.26. Free in depth research on DYAX is available at:

http://www.Investor-Edge.com/DYAX-07Aug2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Investor-Edge.com

SOURCE Investor-Edge

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
What You Need to Know You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technolog...
SYS-CON Events announced today that DXWorldExpo has been named “Global Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Digital Transformation is the key issue driving the global enterprise IT business. Digital Transformation is most prominent among Global 2000 enterprises and government institutions.
SYS-CON Events announced today that NetApp has been named “Bronze Sponsor” of SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. NetApp is the data authority for hybrid cloud. NetApp provides a full range of hybrid cloud data services that simplify management of applications and data across cloud and on-premises environments to accelerate digital transformation. Together with their partners, NetApp em...
One of the biggest challenges with adopting a DevOps mentality is: new applications are easily adapted to cloud-native, microservice-based, or containerized architectures - they can be built for them - but old applications need complex refactoring. On the other hand, these new technologies can require relearning or adapting new, oftentimes more complex, methodologies and tools to be ready for production. In his general session at @DevOpsSummit at 20th Cloud Expo, Chris Brown, Solutions Marketi...
SYS-CON Events announced today that SIGMA Corporation will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. uLaser flow inspection device from the Japanese top share to Global Standard! Then, make the best use of data to flip to next page. For more information, visit http://www.sigma-k.co.jp/en/.
Most of the time there is a lot of work involved to move to the cloud, and most of that isn't really related to AWS or Azure or Google Cloud. Before we talk about public cloud vendors and DevOps tools, there are usually several technical and non-technical challenges that are connected to it and that every company needs to solve to move to the cloud. In his session at 21st Cloud Expo, Stefano Bellasio, CEO and founder of Cloud Academy Inc., will discuss what the tools, disciplines, and cultural...
Why Federal cloud? What is in Federal Clouds and integrations? This session will identify the process and the FedRAMP initiative. But is it sufficient? What is the remedy for keeping abreast of cutting-edge technology? In his session at 21st Cloud Expo, Rasananda Behera will examine the proposed solutions: Private or public or hybrid cloud Responsible governing bodies How can we accomplish?
SYS-CON Events announced today that N3N will exhibit at SYS-CON's @ThingsExpo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. N3N’s solutions increase the effectiveness of operations and control centers, increase the value of IoT investments, and facilitate real-time operational decision making. N3N enables operations teams with a four dimensional digital “big board” that consolidates real-time live video feeds alongside IoT sensor data a...
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
Real IoT production deployments running at scale are collecting sensor data from hundreds / thousands / millions of devices. The goal is to take business-critical actions on the real-time data and find insights from stored datasets. In his session at @ThingsExpo, John Walicki, Watson IoT Developer Advocate at IBM Cloud, will provide a fast-paced developer journey that follows the IoT sensor data from generation, to edge gateway, to edge analytics, to encryption, to the IBM Bluemix cloud, to Wa...
There is huge complexity in implementing a successful digital business that requires efficient on-premise and cloud back-end infrastructure, IT and Internet of Things (IoT) data, analytics, Machine Learning, Artificial Intelligence (AI) and Digital Applications. In the data center alone, there are physical and virtual infrastructures, multiple operating systems, multiple applications and new and emerging business and technological paradigms such as cloud computing and XaaS. And then there are pe...
With the rise of DevOps, containers are at the brink of becoming a pervasive technology in Enterprise IT to accelerate application delivery for the business. When it comes to adopting containers in the enterprise, security is the highest adoption barrier. Is your organization ready to address the security risks with containers for your DevOps environment? In his session at @DevOpsSummit at 21st Cloud Expo, Chris Van Tuin, Chief Technologist, NA West at Red Hat, will discuss: The top security r...
SYS-CON Events announced today that B2Cloud will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. B2Cloud specializes in IoT devices for preventive and predictive maintenance in any kind of equipment retrieving data like Energy consumption, working time, temperature, humidity, pressure, etc.
DevOps at Cloud Expo – being held October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real r...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.